Apr 7, 2025

21st Century Healthcare, 20th Century Rules - Bridging the AI Regulation Gap

Vaishnavi Singh, Christen Rao, Era Sarda, Romano Tucci

The rapid integration of artificial intelligence into clinical decision-making represents both unprecedented opportunities and significant risks. Globally, AI systems are implemented increasingly to diagnose diseases, predict patient outcomes, and guide treatment protocols. Despite this, our regulatory frameworks remain dangerously antiquated and designed for an era of static medical devices rather than adaptive, learning algorithms.

The stark disparity between healthcare AI innovation and regulatory oversight constitutes an urgent public health concern. Current fragmented approaches leave critical gaps in governance, allowing AI-driven diagnostic and decision-support tools to enter clinical settings without adequate safeguards or clear accountability structures. We must establish comprehensive, dynamic oversight mechanisms that evolve alongside the technologies they govern. The evidence demonstrates that one-time approvals and static validation protocols are fundamentally insufficient for systems that continuously learn and adapt. The time for action is now, as 2025 is anticipated to be pivotal for AI validation and regulatory approaches.

We therefore in this report herein we propose a three-pillar regulatory framework:

First, nations ought to explore implementing risk-based classification systems that apply proportionate oversight based on an AI system’s potential impact on patient care. High-risk applications must face more stringent monitoring requirements with mechanisms for rapid intervention when safety concerns arise.

Second, nations must eventually mandate continuous performance monitoring across healthcare institutions through automated systems that track key performance indicators, detect anomalies, and alert regulators to potential issues. This approach acknowledges that AI risks are often silent and systemic, making them particularly dangerous in healthcare contexts where patients are inherently vulnerable.

Third, establish regulatory sandboxes with strict entry criteria to enable controlled testing of emerging AI technologies before widespread deployment. These environments must balance innovation with rigorous safeguards, ensuring new systems demonstrate consistent performance across diverse populations.

Given the global nature of healthcare technology markets, we must pursue international regulatory harmonization while respecting regional resource constraints and cultural contexts.

Reviewer's Comments

Reviewer's Comments

Arrow
Arrow
Arrow

The paper demonstrated a good understanding of the policy problem and landscape. Engaged well with the literature. It also shed some light on technical interpretability problems of AI use in healthcare, but most of the explanations are drawn from existing research. Introducing novel concepts/approaches would strengthen the paper's unique contribution.

Offering multiple solution alternatives for improving AI safety and some potential failure modes was impressive. Insightful contributions on leveraging educational institutes. Strong and detailed implementation plan, but failed to consider the current US AI policy context, which has taken a pro-innovation approach and is dialing back on equity, responsibility, ethics, etc. Being sensitive to the implementation context would make for an implementation plan likely to be successful. Another relevant issue is the US withdrawal from WHO, which should have been considered, given that WHO is one of the main policy actors in this paper. Creative discussion of SupTech applications to advance AI safety. However, could have explained more about what SupTech is at first mention.

This is a well-researched paper that demonstrates the technical aptitude of the authors. However, the technical/science communication aspect could be improved. There was a lot of jargon and complex sentence structures that policymakers to whom it is addressed might struggle to comprehend. Simple sentence structures and reduced usage of jargon in policy papersn(especially those targeted at busy/non-technical policymakers) are best practices.

Cite this work

@misc {

title={

21st Century Healthcare, 20th Century Rules - Bridging the AI Regulation Gap

},

author={

Vaishnavi Singh, Christen Rao, Era Sarda, Romano Tucci

},

date={

4/7/25

},

organization={Apart Research},

note={Research submission to the research sprint hosted by Apart.},

howpublished={https://apartresearch.com}

}

Recent Projects

Apr 27, 2026

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

Apr 27, 2026

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

Apr 27, 2026

PROTEUS (PROTein Evaluation for Unusual Sequences): Structure-Informed Safety Screening for de novo and Evasion-Prone Protein-Coding Sequences

AI protein design tools like RFdiffusion, ProteinMPNN, and Bindcraft make it trivial to produce low-homology sequences that fold into active, potentially hazardous architectures. However, sequence homology-based biosafety screening tools cannot detect proteins that pose functional risk through structurally novel mechanisms with no sequence precedent. We present a tiered computational pipeline that addresses this gap by combining MMseqs2 sequence alignment with structure-based comparison via FoldSeek and DALI against curated toxin databases totaling ~34,000 entries. AlphaFold2-predicted structures are screened for both global fold similarity (FoldSeek) and local active/allosteric site geometry (DALI), capturing convergent functional hazards that sequence screening misses. The pipeline was validated against a panel of toxins, benign proteins, structural mimics, and de novo-designed Munc13 binders, as well as modified ricin variants with residue substitutions. We additionally tested robustness to partial-synthesis evasion, where a bad actor submits multiple shorter coding sequences intended for downstream reassembly into a full toxin-coding gene. We found that while sequence-based screening did not identify any de novo ricin analogues with high certainty, the combined pipeline with FoldSeek and DALI identified all 24 tested de novo ricins as toxic.

Read More

Apr 27, 2026

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

Apr 27, 2026

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.
This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.